All In Biotech

NDA 206911 · Sun Pharm

Bromsite

Bromfenac Sodium · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Mar 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 8, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

64

15 Phase 3, 1 recruiting

FAERS reports

1,020

301 serious, 10 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 8, 2026.

BromSite (bromfenac ophthalmic solution) 0.075% is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. BromSite is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. (1)

Mechanism: Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 8, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
1 products under this application
  • BROMSITE · BROMFENAC SODIUM EQ 0.075% ACID · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Bromfenac" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure146
  • product packaging quantity issue76
  • off label use75
  • product dose omission issue69
  • drug ineffective64
  • eye pain63
  • eye irritation58
  • product storage error39
  • product use issue36
  • visual impairment29
  • ocular hyperaemia28
  • product quality issue28

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20081
20091
20103
20112
201217
20137
20148
201517
201611
201788
2018105
201978
2020261
202173
202257
202375
202483
202563
202669

Recalls

1 FDA enforcement reports for this application.

  • Jan 24, 2019 · Class II · Terminated

    Bromfenac Ophthalmic Solution, 0.075% (Sterile 5 mL) may have a lack of sterility assurance.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bromsite (Bromfenac Sodium)

2024 spending

$1.4M

Beneficiaries

2,644

5,089 claims

Per beneficiary

$527

$51.67 per unit

View as table
YearSpending
2020$9,978,649
2021$9,705,014
2022$6,630,113
2023$3,733,045
2024$1,393,888

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 99 on PubMed

Sponsor: Sun Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.